Health Care And the US Fiscal 1996 Budget

13 February 1995

President Bill Clinton's budget for fiscal 1996, which he has just submitted to Congress, would increase public health expenditures by $735 million, with over 25% of this going to AIDS research and prevention. The other major beneficiaries of the 3.4% increase to the public health agencies would be the National Institutes of Health and the childhood vaccination program.

Specifically, spending on the AIDS program would be raised by $200 million, or 6.8%, with $72 million of the increase going to the NIH for research into AIDS, and $35 million to prevention programs at the Centers for Disease Control and Prevention. Overall, the NIH would get a $468 million increase, 4.1% more than its 1995 budget. Included in its funding would be $15 million to continue identifying human genes and $30 million for a new NIH hospital.

The budget also calls for a net increase of $13 million for the CDC, for the immunization of pre-schoolers, to be added to the $25 million the CDC expects to get through savings from a legislative proposal to reduce vaccine excise taxes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight